![Hydroxychloroquine Impurity E (4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol)](/upload/1124/hy-131262.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Not applicable. As an impurity of Hydroxychloroquine, it does not have a defined pharmacological target. Hydroxychloroquine itself is a synthetic antimalarial agent that also inhibits Toll-like receptor 7/9 (TLR7/9) signaling. This impurity is structurally related to Hydroxychloroquine but lacks therapeutic activity and is used only as an analytical marker.
|
|---|---|
| ln Vitro |
As an analytical reference standard, Hydroxychloroquine Impurity E is not biologically active. Hydroxychloroquine is an antimalarial drug that also inhibits TLR7/9 signaling. This impurity is used for method development and validation, not for therapeutic or biological studies. It serves as a marker for assessing the purity and stability of Hydroxychloroquine drug substance.
|
| ln Vivo |
No in vivo activity has been reported. As a pharmaceutical impurity, it is not administered as a therapeutic agent. It is used exclusively in analytical chemistry applications for quality control. The presence of impurities such as this is regulated by pharmacopoeias to ensure patient safety.
|
| Enzyme Assay |
Hydroxychloroquine Impurity E is used as a reference standard for HPLC analysis. A typical protocol: The compound is dissolved in methanol or mobile phase (e.g., phosphate buffer pH 3.0 with acetonitrile, 85:15) to prepare a stock solution of 0.1-1.0 mg/mL. Working standards are prepared by serial dilution. For identification, 10-20 uL of the standard solution is injected into an HPLC-UV system (detection at 254 nm or 343 nm). The retention time of the impurity is compared to that of the sample to determine its presence. For quantification, a calibration curve (peak area vs. concentration) is constructed.
|
| Cell Assay |
Not applicable. This compound is used for analytical chemistry, not cell-based assays. Hydroxychloroquine Impurity E is not biologically active and is not tested in cell culture. It is stored under recommended conditions (4degC, protect from light) as a solid or in solvent (‑80degC for 6 months, ‑20degC for 1 month).
|
| Animal Protocol |
No animal study protocols are documented. The compound is used exclusively as an analytical standard and is not administered to animals for efficacy or toxicology studies. If used in toxicology studies, it would be as a marker to assess the purity of test articles or to identify degradation products in stability studies.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data has been reported. As an impurity, the compound is not developed as a drug, and its ADME properties have not been characterized. It is structurally similar to Hydroxychloroquine but lacks the terminal hydroxyethyl group, which may affect its absorption, distribution, and elimination profile compared to the parent drug.
|
| Toxicity/Toxicokinetics |
No toxicity data has been reported. The compound is a specified impurity of Hydroxychloroquine. Regulatory limits for impurities are established to ensure that any potential toxicity from impurities is within acceptable levels. The compound is not intended for human consumption as a pure substance.
|
| References |
[1]. Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6.
[2]. Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85(3):429-40. [3]. Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237. |
| Additional Infomation |
Hydroxychloroquine Impurity E is a European Pharmacopoeia (EP) reference standard (EP Impurity E). Its molecular formula is C14H17ClN2O, and its molecular weight is 264.75. The IUPAC name is 4-[(7-chloroquinolin-4-yl)amino]pentan-1-ol. The compound has one defined stereocenter and is a racemic mixture. It is used for quality control and regulatory compliance in pharmaceutical manufacturing.
|
| Molecular Formula |
C14H17CLN2O
|
|---|---|
| Molecular Weight |
264.75058
|
| Exact Mass |
264.103
|
| CAS # |
10500-64-8
|
| PubChem CID |
407550
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.248g/cm3
|
| Boiling Point |
453.7ºC at 760 mmHg
|
| Melting Point |
179-181 ºC
|
| Vapour Pressure |
5.08E-09mmHg at 25°C
|
| Index of Refraction |
1.643
|
| LogP |
3.534
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
18
|
| Complexity |
252
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=C2C(C(NC(C)CCCO)=CC=N2)=CC=1
|
| InChi Key |
BZUKCXDUDOUBKN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H17ClN2O/c1-10(3-2-8-18)17-13-6-7-16-14-9-11(15)4-5-12(13)14/h4-7,9-10,18H,2-3,8H2,1H3,(H,16,17)
|
| Chemical Name |
4-[(7-chloroquinolin-4-yl)amino]pentan-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7771 mL | 18.8857 mL | 37.7715 mL | |
| 5 mM | 0.7554 mL | 3.7771 mL | 7.5543 mL | |
| 10 mM | 0.3777 mL | 1.8886 mL | 3.7771 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
